Navigation

Appraisals in development

This table lists NICE technology appraisals. The list can be sorted by title (alphabetically), wave number, anticipated publication date and process. You can also:

  • click the appraisal title for full details
  • click a column heading to sort the list by that column

More information on the technology appraisals in development list.

Appraisals in development

Results 1-20 of 128

Title Wave Anticipated publication date Referral date Process
Arrythmias - ICDs & Heart failure - cardiac resynchronisation R Sep 2013 MTA
Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201) R Nov 2012 MTA
Atrial fibrillation (stroke prevention) - rivaroxaban 24 May 2012 Dec 2010 STA
Atrial fibrillation - clopidogrel (in combination with aspirin) (suspended) 21 TBC Jul 2009 STA
Atrial fibrillation - dabigatran etexilate 21 TBC Jul 2009 STA
Atrial fibrillation - idraparinux sodium 12 TBC Nov 2005 STA
Atrial fibrillation - vernakalant 26 TBC May 2011 STA
Atrial fibrillation - ximelagatran (suspended) 9 TBC Oct 2000 MTA
Bipolar disorder (children) - aripiprazole 22 Feb 2013 Jan 2010 STA
Bone loss (therapy-induced) in non-metastatic breast cancer - denosumab (suspended) 20 TBC Apr 2009 STA
Bone metastases from solid tumours - denosumab 21 Jun 2012 Apr 2009 MTA
Bowel function - methylnaltrexone 18 TBC Jul 2008 STA
Breast cancer (advanced and/or metastatic) - sunitinib (in combination with capecitabine) - suspended 19 TBC Mar 2009 STA
Breast cancer (advanced or metastatic) - lapatinib (suspended) 13 TBC Dec 2006 STA
Breast cancer (advanced or metastatic) hormone-sensitive - lapatinib (discontinued) 15 TBC Dec 2007 STA
Breast cancer (advanced) - eribulin 23 Dec 2011 Sep 2010 STA
Breast cancer (first line treatment) - sunitinib (in combination with a taxane) (suspended) 19 TBC Mar 2009 STA
Breast cancer (HER2 negative, metastatic) - bevacizumab (2nd line) 27 TBC Nov 2011 STA
Breast cancer (locally advanced or metastatic) - ixabepilone 15 TBC Dec 2007 STA
Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor) 0 TBC Oct 2008 MTA

This page was last updated: 09 February 2012

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright @ 2012 National Institute for Health and Clinical Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright @ 2012 National Institute for Health and Clinical Excellence. All rights reserved.

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright @ 2012 National Institute for Health and Clinical Excellence. All rights reserved.